richtung geben kann...
Hana Biosciences, Inc. (OTC: HNAB), a biopharmaceutical company, engages in the acquisition, development, and commercialization of products for the treatment of medical needs in cancer and immunological diseases. It is developing two product candidates, PT-523 and IPdR. PT-523, a novel nonclassical antifolate, is in Phase I clinical study for the treatment of cancer in humans. The company is also developing IPdR, a novel orally administered prodrug, as a radiosensitizer in various cancers. Hana Biosciences is based in South San Francisco, California. With 9.57 million shares in its float and an undisclosed short position, there is a failure to deliver in shares of HNAB.
also wenn ich das richtige deute, dann sind noch 9,6 mio aktien auf der shortseite :-O
6$ wir kommen...
|